keyword
MENU ▼
Read by QxMD icon Read
search

interferon therapy in hepatitis C

keyword
https://www.readbyqxmd.com/read/29328881/factors-affecting-the-virological-response-among-chronic-hepatitis-c-virus-patients-in-yemen
#1
Zaid Mutahar Mohammed Alezzi, Ayman Yosry Abd El Rehim, Waleed Fouad Fathallah, Mansour Ali Alamrani, Fouad Hezam Othman
Hepatitis C virus (HCV) infection is increasingly seen as a major public health problem, threat, and concern worldwide. In Yemen about 1.7% of the population is infected with chronic hepatitis C. This study aimed to detect the predictors for response to pegylated interferon and ribavirin (Peg-IFN/RBV) in chronic HCV Yemeni patients. The study was conducted on 100 patients with chronic HCV who received Peg-IFN/RBV in the 48th Military Hospital in Sana'a Yemen, from 2011 to 2013. All patients were subjected to complete history taking, thorough clinical examinations, routine laboratory investigation, and abdominal ultrasonography...
January 2018: Journal of Interferon & Cytokine Research
https://www.readbyqxmd.com/read/29327780/systematic-review-with-meta-analysis-effectiveness-and-tolerability-of-interferon-free-direct-acting-antiviral-regimens-for-chronic-hepatitis-c-genotype-1-in-routine-clinical-practice-in-asia
#2
REVIEW
F Ji, B Wei, Y H Yeo, E Ogawa, B Zou, C D Stave, Z Li, S Dang, N Furusyo, R C Cheung, M H Nguyen
BACKGROUND: Direct-acting antiviral (DAA) regimens have shown high efficacy and tolerability for patients with HCV genotype 1/1b (GT1/1b) in clinical trials. However, robust real-world evidence of interferon (IFN)-free DAA treatment for HCV GT1-infected patients in Asia is still lacking. AIM: To systematically review and meta-analyse the effectiveness and tolerability of IFN-free DAA therapy for HCV GT1 infection in Asia. METHODS: We included studies that enrolled adult patients with HCV GT1 infection in routine clinical practice in Asia, using IFN-free DAA regimens, and reported sustained virological response (SVR) after 12/24 weeks end-of-treatment by 31 May 2017...
January 12, 2018: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29325996/direct-acting-antiviral-therapy-for-hepatitis-c-virus-infection-in-the-kidney-transplant-recipient
#3
REVIEW
Donald F Chute, Raymond T Chung, Meghan E Sise
Hepatitis C virus infection (HCV) is a common comorbidity in patients who have undergone kidney transplantation and is associated with increased morbidity and mortality compared with recipients who do not have chronic HCV infection. Because interferon-α-based therapies can precipitate acute rejection, they are relatively contraindicated after kidney transplantation. Thus, the majority of kidney transplant recipients with HCV remain untreated. There are now all-oral, interferon-free direct-acting antiviral therapies for HCV infection that are extremely effective and well tolerated in the general population...
January 9, 2018: Kidney International
https://www.readbyqxmd.com/read/29325280/-clinical-value-of-anti-liver-kidney-microsomal-1-antibody-in-patients-with-liver-disease
#4
Y Han, H P Yan, H Y Liao, L M Sun, Y L Huang, C Y Huang, H P Zhang, X D Zhang, X Q Bian, M X Ren, X F Du, Y M Liu
Objective: To investigate the clinical and laboratory features of patients with liver disease and positive anti-liver/kidney microsomal-1 (anti-LKM-1) antibody, and to provide a reference for clinical diagnosis and differential diagnosis. Methods: The clinical data of patients with positive anti-LKM-1 antibody who were treated in our hospital from 2006 to 2016 were collected, and clinical and laboratory features were analyzed and compared. An analysis was also performed for special cases. Results: The measurement of related autoantibodies was performed for about 100 thousand case-times, and 15 patients were found to have positive anti-LKM-1 antibody...
November 20, 2017: Zhonghua Gan Zang Bing za Zhi, Zhonghua Ganzangbing Zazhi, Chinese Journal of Hepatology
https://www.readbyqxmd.com/read/29325276/-a-clinical-study-of-antiviral-therapy-for-patients-with-compensated-hepatitis-c-cirrhosis
#5
Z W Xie, J P Li, Y J Guan, X Y Zhang, F X Guo, B B Chen, Calvin Q Pan
Objective: To investigate the effect of antiviral therapy on the progression of liver cirrhosis and related predictive factors through a retrospective analysis of patients with compensated hepatitis C cirrhosis. Methods: The patients with compensated hepatitis C cirrhosis who were treated in our hospital from 2004 to 2015 were divided into sustained virologic response (SVR) group, non-SVR (NSVR) group, and untreated group. The baseline features of patients with or without liver cirrhosis were compared to identify the predictive factors for the progression of liver cirrhosis...
November 20, 2017: Zhonghua Gan Zang Bing za Zhi, Zhonghua Ganzangbing Zazhi, Chinese Journal of Hepatology
https://www.readbyqxmd.com/read/29321441/diabetes-mellitus-prevents-an-improvement-in-the-serum-albumin-level-during-interferon-free-sofosbuvir-based-therapy-for-chronic-hepatitis-c-patients-a-multi-institutional-joint-study
#6
Akira Kawano, Hirohisa Shigematsu, Koichiro Miki, Yasunori Ichiki, Chie Morita, Kimihiko Yanagita, Kazuhiro Takahashi, Kazufumi Dohmen, Hideyuki Nomura, Hiromi Ishibashi, Shinji Shimoda
Objective Interferon-free regimens of direct-acting antiviral agents have improved the treatment response for chronic hepatitis C virus (HCV) infection, and improvement in the serum albumin level during interferon-free therapy has been reported. The aim of this study was to identify the factors that influence the improvement in the serum albumin level in patients receiving interferon-free antiviral therapy. Methods This retrospective, multicenter study consisted of 471 Japanese patients with chronic hepatitis and compensated liver cirrhosis infected with HCV who completed 12-week interferon-free sofosbuvir (SOF)-based therapy (SOF plus ledipasvir for genotype 1 [n=276] and SOF with ribavirin for genotype 2 [n=195])...
January 11, 2018: Internal Medicine
https://www.readbyqxmd.com/read/29316747/immunotherapy-for-chronic-hepatitis-b-virus-infection
#7
REVIEW
Antonio Bertoletti, Nina Le Bert
While new therapies for chronic hepatitis C virus infection have delivered remarkable cure rates, curative therapies for chronic hepatitis B virus (HBV) infection remain a distant goal. Although current direct antiviral therapies are very efficient in controlling viral replication and limiting the progression to cirrhosis, these treatments require lifelong administration due to the frequent viral rebound upon treatment cessation, and immune modulation with interferon is only effective in a subgroup of patients...
January 11, 2018: Gut and Liver
https://www.readbyqxmd.com/read/29316039/treatment-of-hcv-infection-in-poland-at-the-beginning-of-the-interferon-free-era-the-epiter-2-study
#8
Robert Flisiak, Dorota Zarębska-Michaluk, Ewa Janczewska, Agnieszka Staniaszek, Andrzej Gietka, Włodzimierz Mazur, Magdalena Tudrujek, Krzysztof Tomasiewicz, Teresa Belica-Wdowik, Barbara Baka-Ćwierz, Dorota Dybowska, Waldemar Halota, Beata Lorenc, Marek Sitko, Aleksander Garlicki, Hanna Berak, Andrzej Horban, Iwona Orłowska, Krzysztof Simon, Łukasz Socha, Marta Wawrzynowicz-Syczewska, Jerzy Jaroszewicz, Zbigniew Deroń, Agnieszka Czauż-Andrzejuk, Jolanta Citko, Rafał Krygier, Anna Piekarska, Łukasz Laurans, Witold Dobracki, Jolanta Białkowska, Olga Tronina, Małgorzata Pawłowska
The aim of the EpiTer-2 study was to analyze patient characteristics and their medication for HCV infection in Poland at the beginning of the interferon-free era. Analysis of data of HCV infected patients treated during the initial period of availability of interferon-free regimens in Poland, who started therapy after 1 July 2015 and had available an efficacy evaluation report before 30 June 2017 was undertaken. A total of 2879 patients with chronic hepatitis C were entered, including 46% with liver cirrhosis...
January 6, 2018: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29316001/directly-observed-therapy-of-chronic-hepatitis-c-with-ledipasvir-sofosbuvir-in-people-who-inject-drugs-at-risk-for-non-adherence-to-direct-acting-antivirals
#9
Angelika Schütz, Stephan Moser, Cornelia Schwanke, Raphael Schubert, Julian Luhn, Enisa Gutic, Tobias Lang, Michael Schleicher, Hans Haltmayer, Michael Gschwantler
An important subgroup of people who inject drugs (PWID) receiving opioid agonist therapy (OAT), cannot be treated in the setting of a hepatology center and would not regularly ingest their medication when handed to them for self-administration. Our hypothesis was that chronic hepatitis C in these patients could be ideally managed if modern, interferon-free regimens were administered together with OAT under direct observation of a physician or nurse at a low-threshold facility. In this open-label, non-interventional, proof-of-concept study (ClinicalTrials...
January 5, 2018: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29299684/treatment-of-hepatitis-c-in-special-populations
#10
REVIEW
Goki Suda, Koji Ogawa, Kenichi Morikawa, Naoya Sakamoto
Hepatitis C virus (HCV) infection is one of the primary causes of liver cirrhosis and hepatocellular carcinoma. In hemodialysis patients, the rate of HCV infection is high and is moreover associated with a poor prognosis. In liver transplantation patients with HCV infection, recurrent HCV infection is universal, and re-infected HCV causes rapid progression of liver fibrosis and graft loss. Additionally, in patients with HCV and human immunodeficiency virus (HIV) co-infection, liver fibrosis progresses rapidly...
January 3, 2018: Journal of Gastroenterology
https://www.readbyqxmd.com/read/29291208/hepatitis-c-infection-in-renal-transplantation-pathogenesis-current-impact-and-emerging-trends
#11
REVIEW
Sailaja Kesiraju, Praneeth Srikanti, S Sahariah
Prevalence of hepatitis C infection, which is associated with mortality and morbidity, is higher in chronic kidney disease patients on hemodialysis and transplant recipients when compared to non HCV infected patients. In addition to the conventional risk factors, HCV infection maybe an additional risk factor in the development of chronic kidney disease. HCV causes adverse effects leading to the poor long term outcome in renal transplant recipients; hepatitis C infection can cause both hepatic as well as extra hepatic complications...
September 2017: Virusdisease
https://www.readbyqxmd.com/read/29290908/liver-decompensation-predicts-ribavirin-overexposure-in-hepatitis-c-virus-patients-treated-with-direct-acting-antivirals
#12
Viola Guardigni, Lorenzo Badia, Matteo Conti, Matteo Rinaldi, Rita Mancini, Pierluigi Viale, Gabriella Verucchi
AIM: To determine whether ribavirin (RBV) concentrations differ according to cirrhosis stage among cirrhotic patients treated with interferon-free regimens. METHODS: We included patients with hepatitis C virus and cirrhosis [Child-Pugh (CP) A or B], Glomerular Filtration Rate ≥ 60 mL/min, who started therapy with DAAs and weight-based RBV between October 2014 and February 2016. RBV plasma levels were assessed during the treatment. We focused our analysis on the first 8 wk of therapy...
December 8, 2017: World Journal of Hepatology
https://www.readbyqxmd.com/read/29288753/impact-of-comorbidities-on-patients-outcomes-after-interferon-free-therapy-induced-viral-eradication-in-hepatitis
#13
Javier Ampuero, Carlota Jimeno, Rosa Quiles, José Miguel Rosales, Susana Llerena, Nieves Palomo, Patricia Cordero, Francisco Javier Serrano, Juan José Urquijo, José María Moreno-Planas, Guillermo Ontanilla, Marta Hernández, Aída Ortega-Alonso, Marta Maraver, Martín Bonacci, Ángela Rojas, Blanca Figueruela, Xavier Forns, Raúl J Andrade, José Luis Calleja, Moisés Diago, Isabel Carmona, Manuel de la Mata, María Buti, Javier Crespo, Juan Manuel Pascasio, José María Navarro, Javier Salmerón, Manuel Romero-Gómez
BACKGROUND&AIMS: Patients with advanced liver fibrosis remain at risk of cirrhosis-related outcomes and those with severe comorbidities could not benefit from Hepatitis C (HCV) eradication. We aimed to collect all-cause mortality and relevant clinical events within the first two years in patients undergoing direct antiviral therapy and determine the impact of a comorbidity-based model on it. METHODS: This was a prospective non-interventional study, from the beginning of direct-acting antiviral therapy to the event of interest (mortality) or up to 2 years of follow-up, including 14 Spanish University Hospitals...
December 27, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/29287014/treatment-of-chronic-hepatitis-c-virus-infection-in-children-a-position-paper-by-the-hepatology-committee-of-european-society-of-paediatric-gastroenterology-hepatology-and-nutrition
#14
Giuseppe Indolfi, Loreto Hierro, Antal Dezsofi, Jörg Jahnel, Dominique Debray, Nedim Hadzic, Piotr Czubowski, Girish Gupte, Yael Mozer-Glassberg, Wendy van der Woerd, Françoise Smets, Henkjan J Verkade, Björn Fischler
OBJECTIVES: In 2017, the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) approved the use of the fixed-dose combination of ledipasvir/sofosbuvir and of the combination of sofosbuvir and ribavirin for treatment of adolescents (12-17 years, weighing more than 35 kg) with chronic hepatitis C virus (HCV) genotype 1, 4, 5 and 6 and genotype 2 and 3 infections, respectively. Although trials with direct acting antivirals (DAAs) are ongoing for younger children, the only available treatment in US and Europe for those < 12 years is still the dual therapy of pegylated interferon (PEG IFN) and ribavirin...
December 28, 2017: Journal of Pediatric Gastroenterology and Nutrition
https://www.readbyqxmd.com/read/29283331/mechanism-of-hepatitis-c-virus-induced-diabetes-mellitus
#15
Usman Ali Ashfaq, Hina Khalid
The hepatitis C virus (HCV), the most predominant cause of liver failure worldwide, is associated with the development of diabetes mellitus (DM) and insulin resistance (IR), both in vivo and in vitro. DM and IR aggravate the rate of fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). Most studies have revealed that patients with HCV are at a greater risk of developing type 2 diabetes (T2D), compared with controls or patients with hepatitis B. In the same way, patients with T2D are highly prone to severe HCV clinical outcomes and increased progression to fibrosis and cirrhosis, ultimately leading to HCC...
2017: Critical Reviews in Eukaryotic Gene Expression
https://www.readbyqxmd.com/read/29283325/emerging-trends-in-non-interferon-based-genotype-specific-antiviral-agents-pharmaceutical-perspectives
#16
Tahir Farooq, Arruje Hameed, Kanwal Rehman, Muhammad Ibrahim, Matloob Ahmed, Tahsin Gulzar, Muhammad Sajid Hamid Akash
Hepatitis C virus (HCV) presents a serious global health threat. Initially, the health-care community mainly focused on interferon (IFN)-based therapeutic options to eradicate HCV, but with the passage of time, these applications became unsuitable due to some serious side effects related to the use of IFN. In recent years, research conducted on different phases of HCV's life cycle has opened a new gateway for the use of a direct-acting new generation of anti-HCV agents. Their safer and ultrarapid response has made possible the introduction of triple therapy and use of IFN-free therapeutic treatment strategies...
2017: Critical Reviews in Eukaryotic Gene Expression
https://www.readbyqxmd.com/read/29279268/direct-acting-antiviral-therapy-enhances-total-cd4-and-cd8-t-cells-responses-but-does-not-alter-t-cells-activation-among-hcv-mono-infected-and-hcv-hiv-1-co-infected-patients
#17
Saeid Najafi Fard, Ivan Schietroma, Giuseppe Corano Scheri, Noemi Giustini, Sara Serafino, Eugenio Nelson Cavallari, Claudia Pinacchio, Gabriella De Girolamo, Giancarlo Ceccarelli, Carolina Scagnolari, Vincenzo Vullo, Gabriella d'Ettorre
AIM: Chronic immune activation and poor T-cell immune response are strongly associated with disease progression and pathogenesis of both hepatitis C virus (HCV) and human immunodeficiency virus (HIV)-1 infections. Little is known about the impact of anti-HCV Interferon (IFN)-free direct-acting antiviral (DAA) therapy on the systemic T-cells activation and patterns of peripheral T-cells producing pro-inflammatory cytokines. PATIENTS AND METHODS: Forty-five subjects including 18 HCV mono-infected, 17 HCV/HIV-1 co-infected patients under antiretroviral therapy (ART), and 10 healthy controls (HCs) were recruited...
December 23, 2017: Clinics and Research in Hepatology and Gastroenterology
https://www.readbyqxmd.com/read/29260001/normalizing-serum-hepcidin-but-not-%C3%AE-1-antitrypsin-level-during-effective-treatment-of-chronic-hepatitis-c
#18
Magdalena Rogalska-Taranta, Jerzy Jaroszewicz, Robert Flisiak
Aim of the study: We investigated the impact of pegylated interferon α-2 in combination with ribavirin (PEG-IFNα/RBV) treatment on hepcidin and α-1-antitrypsin concentrations in the serum of patients with chronic hepatitis C. Material and methods: We measured serum concentrations of hepcidin, prohepcidin and α-1-antitrypsin by enzyme-linked immunosorbent assays in patients with chronic hepatitis C before and during antiviral therapy. Results: Hepcidin concentrations were increased in both genotype 1b and 3a hepatitis C virus (HCV) infected patients as compared with the control group...
December 2017: Clinical and Experimental Hepatology
https://www.readbyqxmd.com/read/29235266/host-genetic-variations-associated-with-disease-progression-in-chronic-hepatitis-c-virus-infection
#19
REVIEW
Kentaro Matsuura, Yasuhito Tanaka
Treatment with recently-developed interferon-free oral regimens combining direct-acting antiviral agents (DAAs) results in the elimination of hepatitis C virus (HCV) in almost all chronic hepatitis C (CHC) patients. In the era of DAAs, surveillance of hepatocellular carcinoma (HCC) after eradication of HCV by anti-HCV therapy is particularly important. As is well known, an advanced state of hepatic fibrosis is the major risk factor for developing HCC. Therefore, an increased understanding of various factors associated with disease progression and development of HCC in CHC patients is essential for implementing personalized treatment and surveillance of disease progression and HCC...
December 13, 2017: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/29233687/interferon-free-direct-acting-antiviral-therapy-for-acute-hepatitis-c-virus-infection-in-hiv-infected-individuals-a-literature-review
#20
REVIEW
Temi Lampejo, Kosh Agarwal, Ivana Carey
Dramatic rises in hepatitis C virus (HCV) coinfection rates in human immunodeficiency virus (HIV)-infected individuals have been observed recently, largely attributable to increasing recreational drug use combined with increased testing for HCV. In the era of direct-acting antiviral (DAA) therapy, treatment of acute HCV infection in HIV-infected individuals with short durations of these drugs may potentially reduce the disease and economic burden associated with HCV infection as well as reducing the likelihood of onward HCV transmission...
November 27, 2017: Digestive and Liver Disease
keyword
keyword
58041
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"